The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Combination efficacy of mTOR and MEK inhibitor in malignant pleural mesothelioma (MPM).
Seiji Matsumoto
No relevant relationships to disclose
Hayato Orui
No relevant relationships to disclose
Ayumi Kuroda
No relevant relationships to disclose
Masaki Hashimoto
No relevant relationships to disclose
Kazue Yoneda
No relevant relationships to disclose
Teruhisa Takuwa
No relevant relationships to disclose
Nobuyuki Kondo
No relevant relationships to disclose
Seiki Hasegawa
No relevant relationships to disclose